Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 1, 2009, Pages 21-26

  Nakamura, Shinko ^a   Iwasaki, Naoko ^a   Funatsu, Hideharu ^a   Kitano, Shigehiko ^a   Iwamoto, Yasuhiko ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Diabetic retinopathy; Polymorphism; VEFG

Indexed keywords

VASCULOTROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE DURATION; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VITREOUS BODY;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 56949097632     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-008-0915-3     Document Type: Article

References (29)

1. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986. doi: 10.1056/NEJM199309303291401
2. UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853. doi: 10.1016/S0140-6736(98)07019-6
3. Cai J, Boulton M (2002) The pathogenesis of diabetic retinopathy: Old concepts and new questions. Eye 16:242-260. doi: 10.1038/sj.eye.6700133
4. Chakrabarti S, Cukiernik M, Hileeto D, Evans T, Chen S (2000) Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy. Diabetes Metab Res Rev 16:393-407. doi: 10.1002/ 1520-7560(0000)9999:9999<::AID-DMRR157>3.0.CO;2-G
5. Ferrara N (2004) Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25:581-611. doi: 10.1210/er.2003-0027
6. Lutty GA, McLeod DS, Merges C, Diggs A, Plouet J (1996) Localization of vascular endothelial growth factor in human retina and choroids. Arch Ophthalmol 114:971-979
7. Funatsu H, Yamashita H, Nakanishi Y, Hori S (2002) Angiotensin IIand vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 86:311-315. doi: 10.1136/bjo.86.3.311
8. Yang B, Cross DF, Ollerenshow M, Millward BA, Demaine AG (2003) Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabet Complications 17:1-6. doi: 10.1016/ S1056-8727(02)00181-2
9. Awata T, Inoue I, Kurihara S, Ohkubo T, Watanabe M, Inukai K et al (2002) A common polymorphism in the 5′-untranslated region of the VEGF gene Is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635-1639. doi: 10.2337/diabetes.51.5.1635
10. Szaflik JP, Kowalski TW, Majsterek I, Borucka AI, Blasiak J, Szaflik J (2007) An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 246(1)39-43
11. Roberto DB, Marina S, Serena G et al (2006) VEGF gene variability and type 1 diabetes: Evidence for a protective role. Immunogenetics 58:107-112. doi: 10.1007/s00251-006-0089-2
12. World Health Organ Tech Rep Ser (1985) Diabetes mellitus. Rep WHO Study Group 727:1-113.
13. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Chah ST et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1(331):1480-1487. doi: 10.1056/NEJM199412013312203
14. Hyodo I, Doi T, Endo H et al (1998) Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 34:2041-2045. doi: 10.1016/S0959-8049(98)00282-2
15. Kitamura Y, Moriguchi M, Kaneko H, Morisaki T, Toyama K, Kamatani N (2002) Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using EM algorithm. Ann Hum Genet 66:183-193. doi: 10.1046/ j.1469-1809.2002.00112.x
16. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Siviridis E (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 6:293-298. doi: 10.1016/j.lungcan.2004.04.037
17. Howell WM, Ali SJ, Rose-Zerilli M, Ye S (2005) VEGF polymorphisms and severity of atherosclerosis. J Med Genet 42:485-490. doi: 10.1136/ jmg.2004.025734
18. Del Bo R, Scarlato M, Ghezzi S, Martinelli B, Fenoglio C, Galbaiati S et al (2005) Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol 57:373-380. doi: 10.1002/ana.20390
19. Szeto CC, Chow KM, Poon P, Szeto CY, Wong TY, Li PK (2004) Genetic polymorphism of VEGF: Impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients. Kidney Int 63:1947-1955. doi: 10.1111/j.1523-1755.2004.00605.x
20. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV et al (2002) Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13:260-264
21. Jin Q, Hemminki K, Forsti A et al (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 1:3647-3653. doi: 10.1158/ 1078-0432.CCR-04-1803
22. Banyasz I, Bokodi G, Vannay A, Szebeni B, Treszl A, Vasarhelyi B, Tulassay T, Szabo A (2006) Genetic polymorphisms of vascular endothelial growth factor and angiopoietin 2 in retinopathy of prematurity. Curr Eye Res 31:685-690. doi: 10.1080/02713680600801123
23. Awata T, Kurihara S, Takata N, Neda T, Iizuka H, Ohkubo T et al (2005) Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macula retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 333:679-685. doi: 10.1016/ j.bbrc.2005.05.167
24. Suganthalakshmi B, Anand R, Kim R, Mahalakshmi R, Karthikprakash S, Namperumalsamy P et al (2006) Association of VEGF and eNOS gene polymorphism in type 2 diabetic retinopathy. Mol Vis 12:336-341
25. Steto C-C, Chow K-M, Poon P, Steto CY-K, Wong TY-H, Li PK-T (2004) Genetic polymorphism of VEGF: Impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients. Kidney Int 65:1947-1955. doi: 10.1111/j.1523-1755.2004.00605.x
26. Burgos R, Simo R, Audi L, Mateo C, Mesa J, Garcia-Ramirez M et al (1997) Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia 40:1107-1109. doi: 10.1007/s001250050794
27. Aiello LP, Iwamoto MA et al (1995) Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 113:1538-1544
28. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM et al (2003) Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 9:210-216
29. Tolentino M, Brucker AJ, Fosnot J, Ying GS, Wu IH, Malik G et al (2004) Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 24:132-138. doi: 10.1097/00006982-200402000-00018